Ethical and Scientific Issues in Studying the Safety of Approved Drugs

Afbeeldingen

Artikel vergelijken

Samenvatting

An estimated 48 percent of the population takes at least one prescription drug in a given month. Drugs provide great benefits to society by saving or improving lives. Many drugs are also associated with side effects or adverse events, some serious and some discovered only after the drug is on the market. The discovery of new adverse events in the postmarketing setting is part of the normal natural history of approved drugs, and timely identification and warning about drug risks are central to the mission of the Food and Drug Administration (FDA). Not all risks associated with a drug are known at the time of approval, because safety data are collected from studies that involve a relatively small number of human subjects during a relatively short period. Written in response to a request by the FDA, Ethical and Scientific Issues in Studying the Safety of Approved Drugs discusses ethical and informed consent issues in conducting studies in the postmarketing setting. It evaluates the strengths and weaknesses of various approaches to generate evidence about safety questions, and makes recommendations for appropriate followup studies and randomized clinical trials. The book provides guidance to the FDA on how it should factor in different kinds of evidence in its regulatory decisions. Ethical and Scientific Issues in Studying the Safety of Approved Drugs will be of interest to the pharmaceutical industry, patient advocates, researchers, and consumer groups. Table of Contents Front Matter Abstract Summary 1 Introduction 2 Incorporating Benefit and Risk Assessment and BenefitRisk Management into Food and Drug Administration Decision-Making 3 Evidence and Decision-Making 4 Selection and Oversight of Required Postmarketing Studies 5 Synthesis Appendix A: Other Elements of the Food and Drug Administration Amendments Act Appendix B: Committee's Letter Report Appendix C: Open Session Agendas Appendix D: Decision Conferencing and Multicriteria Decision Analysis Appendix E: Benefit and Risk Assessment and Management Plan Document Template Appendix F: Committee Biosketches

Productspecificaties

Inhoud

Taal
en
Bindwijze
Paperback
Oorspronkelijke releasedatum
30 augustus 2012
Aantal pagina's
275
Illustraties
Nee

Overige kenmerken

Editie
1
Extra groot lettertype
Nee
Studieboek
Nee
Verpakking breedte
152 mm
Verpakking hoogte
229 mm
Verpakking lengte
229 mm
Verpakkingsgewicht
499 g

EAN

EAN
9780309218139

Je vindt dit artikel in

Beschikbaarheid
Leverbaar
Taal
Engels
Boek, ebook of luisterboek?
Boek
Studieboek of algemeen
Studieboeken
Nog geen reviews

Kies gewenste uitvoering

Bindwijze : Paperback

Prijsinformatie en bestellen

De prijs van dit product is 56 euro en 99 cent.
3 weken
Verkoop door bol
  • Prijs inclusief verzendkosten, verstuurd door bol
  • Ophalen bij een bol afhaalpunt mogelijk
  • 30 dagen bedenktijd en gratis retourneren
  • Dag en nacht klantenservice

Lijst met gekozen artikelen om te vergelijken

Vergelijk artikelen